Abstract:Abstract Background In spite of the significant escalation in the depth of our conception and regulation of breast cancer over the past decades, the malady is still a serious community health challenge globally and poses a substantial tasks. Selective estrogen modulators (SERMs) such as Tamoxifen are approved for the therapy of this illness but developed drug resistance and unwanted side effects such as endometrial cancer caused by the long-term Tamoxifen chemotherapy limit their therapeutic applicability. Hence, developing new ER + drugs with better therapeutic effect is strongly needed. In an attempt to overcome this challenge, this research is aimed at designing novel chromen-2-one analogues with better inhibition capacity against MCF-7 breast cancer cell line via structural modification of the reference compound and predict their activities using a developed QSAR model. Results Four models were developed, and the first was selected for the design as it has the highest statistical parameters such as: coefficient of determination ( R 2 = 0.950), cross-validation coefficient ( Q cv 2 = 0.912), adjusted R 2 ( R adj 2 = 0.935), and external validation R 2 ( R pred 2 = 0.7485). Twelve (12) new novel chromen-2-one analogs were designed through structural modification of the reference compound. Their activities was predicted using the selected model, and their pIC 50 was found to be better than that of the reference compound and standard drug (Tamoxifen) used in the research. Results of pharmacokinetic study of the designed compounds revealed that they possess drug-likeness properties as none of them violated the Lipinski’s rule of five while ADMET studies confirmed designed compounds 6, 8, 11 and 12 as orally safe and non-toxic. Furthermore, molecular docking analysis was performed between these orally safe designed compounds and the active site of the ER + receptor and the result showed that they have higher binding affinities than the reference compound and the standard drug used for this research. Conclusion Hence, designed compounds 6, 8, 11 and 12 can be used as novel ER + breast cancer drug candidates after performing in vivo and in vitro studies.

Design, Synthesis and Biological Evaluation of Novel Indone Derivatives As Selective ERβ Modulators

Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents

Design, Synthesis and Evaluation of 6-Aryl-indenoisoquinolone Derivatives Dual Targeting ERα and VEGFR-2 As Anti-Breast Cancer Agents.

Design, Synthesis and Biological Evaluation of Novel 2-Methoxyestradiol Analogs As Dual Selective Estrogen Receptor Modulators (serms) and Antiangiogenic Agents

Design and synthesis of novel benzothiophene analogs as selective estrogen receptor covalent antagonists against breast cancer

Synthesis and Biological Evaluation of 3-Aryl-quinolin Derivatives As Anti-Breast Cancer Agents Targeting ERα and VEGFR-2.

Synthesis and Estrogen-Like Activity of Resveratrol Analogues

Synthesis and Biological Evaluation of 2,3-Diaryl Isoquinolinone Derivatives As Anti-Breast Cancer Agents Targeting ERα and VEGFR-2.

Computational modeling, ligand-based drug design, drug-likeness and ADMET properties studies of series of chromen-2-ones analogues as anti-cancer agents

Synthesis and biological evaluation of 4,6-diaryl-2-pyrimidinamine derivatives as anti-breast cancer agents.

Rational Design and Optimization of Selenophenes with Basic Side Chains As Novel Potent Selective Estrogen Receptor Modulators (serms) for Breast Cancer Therapy.

Discovery of Thieno[2,3-e]indazole Derivatives As Novel Oral Selective Estrogen Receptor Degraders with Highly Improved Antitumor Effect and Favorable Druggability

Synthesis, Characterization of a Series of Daidzein Derivatives As Selective Estrogen Receptor Modulator

Synthesis of 2,2-dimethyl-chroman-based stereochemically flexible and constrained anti-breast cancer agents

Benzothiophene Derivatives As Selective Estrogen Receptor Covalent Antagonists: Design, Synthesis and Anti-Erα Activities.

Novel SERMs Based on 3-Aryl-4-aryloxy-2h-chromen-2-one Skeleton - A Possible Way to Dual ERα/VEGFR-2 Ligands for Treatment of Breast Cancer.

Synthesis and Characterization of a Series of Genistein Derivatives As Selective Estrogen Receptor Modulators

Synthesis and Bio-evaluation of 2-Alkyl Substituted Fluorinated Genistein Analogues Against Breast Cancer.

Novel Hybrid Conjugates with Dual Suppression of Estrogenic and Inflammatory Activities Display Significantly Improved Potency Against Breast Cancer

Discovery of Novel 2H-Chromene-3-carbonyl Derivatives As Selective Estrogen Receptor Degraders (serds): Design, Synthesis and Biological Evaluation.

X-ray Crystallography Study and Optimization of Novel Benzothiophene Analogs As Potent Selective Estrogen Receptor Covalent Antagonists (sercas) with Improved Potency and Safety Profiles.